Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-label, Fixed-sequence, Cross-over Trial to Assess the Effects of a Single Dose of Prazosin or Propranolol in the Presence of Brexpiprazole/Sertraline at Steady-state on Blood Pressure

Next Previous
Trial Profile

A Phase 1, Open-label, Fixed-sequence, Cross-over Trial to Assess the Effects of a Single Dose of Prazosin or Propranolol in the Presence of Brexpiprazole/Sertraline at Steady-state on Blood Pressure

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 31 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brexpiprazole (Primary) ; Prazosin (Primary) ; Propranolol (Primary) ; Sertraline (Primary)
  • Indications Anxiety disorders; Depressive disorders; Obsessive-compulsive disorders; Panic disorder; Post-traumatic stress disorders
  • Focus Therapeutic Use
  • Sponsors Otsuka Pharmaceutical

Most Recent Events

  • 22 Jan 2024 Status changed from recruiting to discontinued due to some implausible blood pressure values being captured, which was the primary endpoint of the study. The discontinuation was not for any safety reason.
  • 08 Aug 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top